ClinicalTrials.gg
Drug

AZD1390 clinical trials

Also written AZD1390.

studies test it
9
open now
3
in phase 3
1
first study started
2017

How each study uses AZD1390 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the AZD1390 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AZD1390
7

Studies by the year they started

9 studies that test it; most in 2022 (2)

Studies that test AZD1390, by start year
YearStudies
20171
20181
20191
20211
20222
20231
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
7
Phase 2
1
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 6

AstraZeneca (3) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · Nader Sanai (1) · Global Coalition for Adaptive Research (1) · University of Leeds (1) · The Netherlands Cancer Institute (1)

Often tested with

Tested in the same studies.

Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · Tinostamustine (1) · Olaparib (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses AZD1390 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 9

Codes

What other systems call AZD1390 · ClinicalTrials.gg INT002042

  • MeSH (NLM) C000729307AZD1390One source ClinicalTrials.gov
  • NCI Thesaurus C150167ATM Kinase Inhibitor AZD1390One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.